An Open-label, Single-dose, Parallel-group Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Velufenacin (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Dong-A ST
- 26 Jun 2024 Status changed from recruiting to completed.
- 10 May 2023 Status changed from not yet recruiting to recruiting.
- 17 Apr 2023 New trial record